Compare Emerson Electric Co. (EMR) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Eli Lilly And Co — how do they compare? Emerson Electric Co. trades at $159.6 (market cap $88.72B), while Eli Lilly And Co trades at $1,165.25 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 11.7× Emerson Electric Co.'s market cap, and Emerson Electric Co. pays the higher dividend (1.4%). Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and Eli Lilly And Co for 93 Days on average.
| EMR | LLY | |
|---|---|---|
Market Cap | $88.72B | $1.04T |
Volume | 2,355,255 | 3,064,878 |
Sector | Industrials | Health |
52-Week High | $164.38 | $1.28K |
52-Week Low | $123.30 | $799.57 |
Typical Hold Time | 81 Days | 93 Days |
Enterprise Value | $99.80B | $1.09T |
Dividend Yield | 1.4% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $159.22, down 1.34% today, with a bullish technical signal and strong analyst support. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $1.71 exceeding the $1.68 estimate. Revenue growth is steady, projected at $18.6B for 2026, while profitability metrics like a 13.83% net margin and 12.81% ROE reflect operational strength. The stock faces resistance near $160, with support at $158.
Outlook remains positive given earnings momentum and a consensus price target of $165.90, implying ~4% upside. Risks include debt levels rising to 31.26% of assets in 2025 and macroeconomic pressures on industrial demand. Institutional sentiment is bullish, with 53% of analysts rating Buy.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.
Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
